Insider · CIK 0001340610
Cameron John Reynolds
Files at VNRX (VOLITIONRX LTD). First filing Dec 10, 2024, latest Nov 17, 2025.
Cameron John Reynolds files SEC Form 4 as CEO, president and director at VNRX (VOLITIONRX LTD). Since Dec 10, 2024, Cameron John Reynolds has reported 7 open-market buys worth $219k and 0 open-market sells worth $0, the latest filed on Nov 17, 2025.
A track record needs three past buys with six months of prices behind them; Cameron John Reynolds has 0, so none is measured yet.
The newest scored trade: bought $7,000 of VNRX on Nov 17, 2025, filed Nov 17, 2025, scored 43 (moderate). In the last 12 months: 2 buys worth $63k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
VNRX: VOLITIONRX LTD
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | VNRXbuy VOLITIONRX LTD | $7,000 20,000 shares | +1% | 0% from low-65% from high | |
| 70Notable | VOLITIONRX LTD | $56k 110,000 shares | +5% | +10% from low-50% from high | |
| 29Weak | VNRXbuy VOLITIONRX LTD | $9,885 15,000 shares | +1% | +57% from low-28% from high | |
| 53Moderate | VOLITIONRX LTD | $50k 78,125 shares | +3% | +52% from low-30% from high | |
| 41Moderate | VOLITIONRX LTD | $7,373 12,500 shares | +1% | +43% from low-32% from high | |
| 46Moderate | VOLITIONRX LTD | $8,730 20,000 shares | +1% | 0% from low-52% from high | |
| 52Moderate | VOLITIONRX LTD | $80k 139,811 shares | +7% | - |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | VNRX VOLITIONRX LTD | AGrant or award Common Stock | +486,000 | $0.00 | $0 | 3,115,547 | Feb 27, 2026 |
| Jan 22, 2026 | VNRX VOLITIONRX LTD | AGrant or award Common Stock | +74,700 | $0.00 | $0 | 2,629,547 | Jan 23, 2026 |
| Nov 17, 2025 | VNRX VOLITIONRX LTD | POpen-market purchase Common Stock | +20,000 | $0.35 | $7,000 | 2,554,847 | Nov 17, 2025 |
| Oct 14, 2025 | VNRX VOLITIONRX LTD | POpen-market purchase Common Stock | +110,000 | $0.51 | $56k | 2,534,847 | Oct 15, 2025 |
| Oct 14, 2025 | VNRX VOLITIONRX LTD | POpen-market purchase Warrant (Right to Buy)derivative | +110,000 | $0.01 | $1,100 | 110,000 | Oct 15, 2025 |
| Sep 12, 2025 | VNRX VOLITIONRX LTD | POpen-market purchase Common Stock | +15,000 | $0.66 | $9,885 | 2,624,847 | Sep 15, 2025 |
| Aug 5, 2025 | VNRX VOLITIONRX LTD | POpen-market purchase Common Stock | +78,125 | $0.64 | $50k | 2,609,847 | Aug 6, 2025 |
| Jul 24, 2025 | VNRX VOLITIONRX LTD | AGrant or award Common Stock | +200,000 | $0.00 | $0 | 2,531,722 | Jul 25, 2025 |
| Jun 12, 2025 | VNRX VOLITIONRX LTD | POpen-market purchase Common Stock | +12,500 | $0.59 | $7,373 | 2,331,722 | Jun 16, 2025 |
| May 19, 2025 | VNRX VOLITIONRX LTD | POpen-market purchase Common Stock | +20,000 | $0.44 | $8,730 | 2,319,222 | May 19, 2025 |
| Dec 9, 2024 | VNRX VOLITIONRX LTD | POpen-market purchase Common Stock | +139,811 | $0.57 | $80k | 2,117,404 | Dec 10, 2024 |
Questions about Cameron John Reynolds
Answered from the filings on this page, as of the latest one.
Is Cameron John Reynolds buying or selling?
In the last 12 months Cameron John Reynolds reported 2 open-market buys worth $63k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $7,000 of VNRX on Nov 17, 2025. Grants, option exercises and tax withholding are not counted.
How did Cameron John Reynolds's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Cameron John Reynolds has 0.
Where does Cameron John Reynolds file Form 4?
Cameron John Reynolds has filed Form 4 at VNRX (VOLITIONRX LTD) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.